Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.71 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.71 |
| ▸ | FASN | P49327 | 1/20 | 0.68 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.66 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.64 |
| ▸ | TP53 | P04637 | 1/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.62 |
| ▸ | POLB | P06746 | 2/20 | 0.61 |
| ▸ | MEN1 | O00255 | 2/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.61 |
| ▸ | GAA | P10253 | 1/20 | 0.61 |
| ▸ | HTT | P42858 | 1/20 | 0.61 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5450137 | 0.85 | ALDH1A1 (0.68) | ALDH1A1POLBMEN1KMT2AGAA | |
| Sulfamerazine SCHEMBL28028780 | 0.83 | MAPT (0.94) | MAPTCYP2C9FASNNPSR1MAPK1 | |
| Sulfamerazine SCHEMBL33999 | 0.83 | MAPT (1.00) | MAPTCYP2C9FASNNPSR1MAPK1 | |
| Sulfamerazine SCHEMBL29538415 | 0.83 | MAPT (1.00) | MAPTCYP2C9FASNNPSR1MAPK1 | |
| SCHEMBL14081433 | 0.83 | MAPT (0.78) | MAPTCYP2C9FASNNPSR1MAPK1 | |
| SCHEMBL3121930 | 0.83 | AURKA (0.66) | MAPTTP53ALDH1A1POLBMEN1 | |
| Sulfamerazine SCHEMBL8159446 | 0.82 | MAPT (0.92) | MAPTCYP2C9FASNNPSR1MAPK1 | |
| Sulfamerazine SCHEMBL93591 | 0.82 | MAPT (0.97) | MAPTCYP2C9FASNNPSR1MAPK1 | |
| Sulfamerazine SCHEMBL5871007 | 0.82 | MAPT (0.97) | MAPTCYP2C9FASNNPSR1MAPK1 | |
| SCHEMBL17507876 | 0.81 | FASN (1.00) | MAPTCYP2C9FASNMAPK1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020183011-A1 | HTR1D INHIBITORS AND USES THEREOF IN THE TREATMENT OF CANCER | INSTITUT CURIE (FR) | 2020-09-17 | — | — | WO | disclosed |
| US-20070010526-A1 | Therapeutic isoquinoline compounds | ASTRAZENECA AB (SE) | 2007-01-11 | — | — | US | disclosed |
| EP-1451172-A1 | THERAPEUTIC ISOQUINOLINE COMPOUNDS | AstraZeneca AB (SE) | 2004-09-01 | — | — | EP | disclosed |
| WO-2003037887-A1 | THERAPEUTIC ISOQUINOLINE COMPOUNDS | ASTRAZENECA AB (SE) | 2003-05-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070010526-A1 | Therapeutic isoquinoline compounds | HTR1B, HTR1D, HTR1A | MAPT 577/4885CYP2C9 725/4885FASN 3278/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.